Healthcare Unfiltered

Chadi sits down with Gregory Vidal, MD, PhD, medical oncologist at the West Cancer Center, for a comprehensive, state-of-the-field discussion on triple-negative breast cancer (TNBC). Dr. Vidal walks listeners through how TNBC emerged as a diagnosis of exclusion, who is most commonly affected, current treatment paradigms and sequencing in early-stage and metastatic disease, and key considerations around surgery, recurrence risk, and unresolved questions. The conversation also explores modern decision-making in metastatic TNBC, including PD-L1 testing, first- and second-line strategies, antibody–drug conjugates versus chemotherapy, PARP inhibitors for BRCA-mutated disease, and the critical role of clinical trials in shaping the future of care.Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

Jonathan Chen, MD, PhD—Assistant Professor of Medicine and Biomedical Informatics at Stanford University—joins the show and offers a pragmatic look at how data science and AI can be meaningfully integrated into everyday medical practice. He breaks down how complex clinical data can be translated into intuitive, real-world use cases, from algorithm-driven decision support in cancer diagnosis to recommendations that fit seamlessly into day-to-day clinician workflows. The conversation also explores whether these approaches can scale across specialties and procedures, while thoughtfully addressing the ethical considerations that come with deploying AI in clinical care.Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

Chadi sits down with Sanjay Juneja, MD—board-certified hematologist/oncologist, healthcare futurist, and physician executive—to demystify artificial intelligence and explain what it truly means for patient care today and in the years ahead. Dr. Juneja breaks down how AI is already influencing healthcare broadly and oncology specifically, from generative AI applications to emerging tools that can analyze voice patterns to estimate physiologic markers like glucose levels. They also explore where AI is headed over the next 5–10 years, the risks and potential for misuse outside of medicine, strategies to minimize AI error, and whether human experts will continue to play a critical role between AI and patients.Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

In this reflective and wide-ranging conversation, ASCO President Robin Zon, MD, FACP, FASCO, looks back on the formative moments that led her to oncology and the grit required to build a thriving community-based research program while balancing the demands of leadership, motherhood, and clinical practice. She shares the path that took her from ASCO member and fellow in 1997 to the presidency, unpacking the three-pillar theme she crafted for her term and the accomplishments she’s most proud of, especially those rooted in her identity as a community oncologist connecting with colleagues nationwide. Dr. Zon also weighs in on emerging innovations like AI, the evolving realities of community practice, and the broader challenges she believes oncology and the healthcare system must confront in the years ahead.Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

Chadi sits down with Dr. Sairah Ahmed just ahead of the ASH Annual Meeting for a comprehensive deep dive into the state of Hodgkin Lymphoma management in 2026. Dr. Ahmed walks through how clinicians should interpret the newest data releases, revisits whether histologic subtyping still influences decision-making in an era increasingly shaped by biomarkers, and details her practical framework for approaching patients with stage I/II disease—including when and how radiation therapy still plays a meaningful role. She further explores the strength and limitations of interim PET, whether treatment should truly pivot based on those scans, and how nivolumab is now being deployed across frontline, relapsed/refractory, and post-transplant settings. Rounding out the discussion, Dr. Ahmed outlines how she manages advanced-stage disease with particular attention to insights and implications from SWOG S1826, highlights immune-related toxicities clinicians must watch for, clarifies the evolving role of autologous transplant and the preferred sequence of prior therapies, and offers an inside look at the most important agents and strategies moving through the Hodgkin Lymphoma pipeline.Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

Journalist Erin O'Hearn, a mother and caregiver with a rich background in broadcast reporting, shares her poignant journey as both a patient with Crohn's disease and a long-term caregiver. She highlights how AI could have alleviated the emotional and logistical challenges in her care experience. Erin discusses the MAHA movement and emphasizes the importance of combining AI with genuine human connection. She offers practical advice for caregivers, advocating for open conversations and the need to seek support during tough times.

Chadi sits down with Dr. Debra Patt, Executive Vice President of Texas Oncology and President of the Community Oncology Alliance (COA), for an in-depth conversation about the evolving landscape of community oncology. Dr. Patt outlines her vision for bringing innovation and artificial intelligence into routine cancer care—addressing challenges from clinical decision-making to physician burnout—while ensuring equitable access to cutting-edge treatments across all practice settings. She also discusses her leadership role on the ASCO Board, her efforts to expand clinical research opportunities to smaller community sites, and how these initiatives collectively aim to advance the global standard of oncology care.Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

Chadi resumes his WCLC review with Dr. Eric Singhi of The University of Texas MD Anderson Cancer Center, exploring the most significant updates in mutation-driven lung cancer presented at this year’s meeting. The discussion dives into advances in sequencing and molecular profiling to identify actionable genomic alterations (AGAs) and how these findings are transforming both early- and late-stage treatment strategies. Dr. Singhi highlights key data from the ADAURA, TARGET, and NAUTIKA1 studies, as well as the expanding role of EGFR-, ALK-, BRAF-, and KRAS-targeted therapies in neoadjuvant and adjuvant settings. The conversation also examines the challenges of financial toxicity, decisions around adjuvant treatment cessation, and the nuanced management of locally advanced and stage IV EGFR-positive disease in the era of precision oncology.Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA 

Dr. Estelamari Rodriguez, thoracic oncologist at the University of Miami’s Sylvester Comprehensive Cancer Center, joins the show to break down the latest advances in non-mutation driven and small cell lung cancer presented at the World Conference on Lung Cancer (WCLC) and how they translate into everyday clinical practice. She discusses pivotal studies including the ALCHEMIST trial exploring adjuvant therapy in ALK-fusion–positive early-stage lung cancer, PACIFIC-2 assessing concurrent immunotherapy and radiation, and the FLAURA2 and MARIPOSA trials redefining targeted approaches for advanced disease. The conversation also delves into next-generation drugs transforming outcomes in extensive-stage small cell lung cancer, updates in mesothelioma, and the expanding use of liquid biopsy—now a cornerstone for diagnosis, monitoring, and guiding precision therapy for all patients.Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA 

Returning guest Dr. Amer Zeidan of Yale Medicine and Smilow Cancer Hospital joins to discuss how clinicians should approach low-risk Myelodysplastic Syndrome (MDS), which is most often managed in community settings. He breaks down how to risk-stratify patients using molecular and prognostic markers, when to treat versus observe, and his preferred first-line therapies in today’s landscape. Dr. Zeidan also delves into the COMMANDS trial and the role of luspatercept, emerging questions shaping the future of low-risk MDS management, and offers a preview of high-risk MDS developments, including insights from the VERONA study.Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA